कंपनी का अवलोकन
Krystal Biotech, Inc. operates as a commercial-stage biotechnology entity dedicated to the discovery, development, manufacturing, and commercialization of genetic medicines aimed at addressing high unmet medical needs within the United States healthcare sector. As a company situated in the biotechnology industry, its activities focus on delivering specialized therapeutic solutions, specifically commercializing treatments like VYJUVEK for conditions requiring advanced medical intervention. The organization maintains a workforce of 295 employees and holds a substantial market capitalization of $7.60B, reflecting significant investor confidence in its asset base and potential for value generation. With annual revenue reaching $389.13M, these financial figures indicate that Krystal Biotech has achieved a scale typical of established commercial-stage firms rather than early-stage research entities, suggesting a mature business model capable of generating substantial cash flows from its product portfolio.
वित्तीय स्वास्थ्य
The company reported total revenue of $389.13M for the trailing twelve months, accompanied by a net income of $204.83M and an EBITDA of $162.92M, highlighting a robust bottom line derived from its core operations. The substantial gap between revenue and net income reveals a highly efficient cost structure where the company retains a significant portion of top-line sales as profit after accounting for all expenses, including taxes and non-operating items. Free cash flow stands at $93.93M, which provides the entity with considerable financial flexibility to fund future research and development initiatives, pursue strategic acquisitions, or return capital to stakeholders without relying on external financing. Profitability is underscored by a gross margin of 94.1%, an operating margin of 41.3%, and a profit margin of 52.6%, all of which indicate exceptional pricing power and low cost of goods sold relative to sales volume. The balance sheet is characterized by high liquidity, holding $827.79M in cash against a minimal debt load of $9.34M, resulting in a debt-to-equity ratio of 0.77 that signifies a conservative and low-leverage financial position. Short-term liquidity is further reinforced by a current ratio of 9.95, demonstrating that the company possesses nearly ten times the current assets required to cover its current liabilities, thereby ensuring stability against immediate financial obligations. Additionally, the return on equity is 18.9% and the return on assets is 8.4%, metrics that reveal management's effectiveness in utilizing shareholder capital and total assets to generate superior returns compared to industry averages.
मूल्यांकन आकलन
Valuation metrics for Krystal Biotech include a trailing P/E ratio of 37.71 and a forward P/E of 24.42, implying that the market expects earnings to grow significantly in the coming years to justify the current multiple compression. The difference between these two ratios suggests an anticipated improvement in profitability, as the forward P/E is lower than the trailing P/E, indicating that investors price in future earnings expansion. The price-to-book ratio is recorded at 6.18, which indicates that the market values the company's equity at a significant premium over its accounting book value, a common phenomenon for biotechnology firms with intangible assets and strong intellectual property portfolios. Alternative valuation measures such as a price-to-sales ratio of 19.54 and an EV/EBITDA of 41.33 suggest that the stock is priced based on growth expectations and revenue generation potential rather than current earnings yield alone. Regarding price volatility, the 52-week trading range spans from a low of $122.80 to a high of $298.30, providing a context for where the current market price sits relative to recent historical extremes. The stock exhibits a beta of 0.54, indicating that its price movements are less volatile than the broader market, suggesting a defensive characteristic often found in sectors with established product pipelines and stable cash flows.
Growth & Income
Growth dynamics are characterized by a revenue growth rate of 17.5% year-over-year and an earnings growth rate of 11.6% year-over-year, indicating that while earnings are expanding, they are growing at a slower pace than revenue, which may reflect one-time costs, margin compression, or heavy investment in scaling operations. The company does not distribute dividends to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which signifies that all net income is retained within the business to fund growth initiatives rather than being distributed as cash payouts. This reinvestment strategy is typical for commercial-stage biotechnology companies that prioritize funding research and development or expanding manufacturing capabilities over immediate income generation for investors. Overall, Krystal Biotech presents a profile focused on capital appreciation through organic growth and market expansion rather than income generation via dividends, aligning its capital allocation strategy with the long-term value creation goals of its shareholders in the healthcare sector.